Xufeng Chen

Xufeng Chen

Auto-generated profile, based on publicly available information

Xufeng Chen

Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in Blood
Verified
Journal Article
Open access
PDF file
CDCourtney Dinardo
Courtney Dinardo
ITIng Soo Tiong
Ing Soo Tiong
AQA. Quaglieri
A. Quaglieri
SMS. MacRaild
S. MacRaild
SLSanam Loghavi
Sanam Loghavi
Andrew H WeiAndrew H Wei
Andrew H Wei
The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of durable remission, response followed by relapse (adaptive resistance), or refractory disease (primary resistance). High response rates and durable remissions were typically associated with NPM1 or IDH2 mutations, with prolonged molecular remissions prevalent for NPM1 mutations. Primary and adaptive resistance to venetoclax-based combinations was most commonly characterized by acquisition or enrichment of clones activating signaling pathways such as FLT3 or RAS or biallelically perturbing TP53. Single-cell studies highlighted the polyclonal nature of intratumoral resistance mechanisms in some cases. Among cases that were primary refractory, we identified heterogeneous and sometimes divergent interval changes in leukemic clones within a single cycle of therapy, highlighting the dynamic and rapid occurrence of therapeutic selection in AML. In functional studies, FLT3 internal tandem duplication gain or TP53 loss conferred cross-resistance to both venetoclax and cytotoxic-based therapies. Collectively, we highlight molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies.

24 April 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
CGChristina Glytsou
Christina Glytsou
XCXufeng Chen
Xufeng Chen
EZEmmanouil Zacharioudakis
Emmanouil Zacharioudakis
WAWafa Al-Santli
Wafa Al-Santli
HZHua Zhou
Hua Zhou
IAIannis Aifantis
Iannis Aifantis
BH3 mimetics are used as an efficient strategy to induce cell death in several blood malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 antagonist, is used clinically in combination with hypomethylating agents for the treatment of AML. Moreover, MCL1 or dual BCL-2/BCL-xL antagonists are under investigation. Yet, resistance to single or combinatorial BH3-mimetic therapies eventually ensues. Integration of multiple genome-wide CRISPR/Cas9 screens revealed that loss of mitophagy modulators sensitizes AML cells to various BH3 mimetics targeting different BCL-2 family members. One such regulator is MFN2, whose protein levels positively correlate with drug resistance in patients with AML. MFN2 overexpression is sufficient to drive resistance to BH3 mimetics in AML. Insensitivity to BH3 mimetics is accompanied by enhanced mitochondria–endoplasmic reticulum interactions and augmented mitophagy flux, which acts as a prosurvival mechanism to eliminate mitochondrial damage. Genetic or pharmacologic MFN2 targeting synergizes with BH3 mimetics by impairing mitochondrial clearance and enhancing apoptosis in AML. Significance: AML remains one of the most difficult-to-treat blood cancers. BH3 mimetics represent a promising therapeutic approach to eliminate AML blasts by activating the apoptotic pathway. Enhanced mitochondrial clearance drives resistance to BH3 mimetics and predicts poor prognosis. Reverting excessive mitophagy can halt BH3-mimetic resistance in AML. This article is highlighted in the In This Issue feature, p. 1501

13 October 2025 in Nature Neuroscience
Verified
Journal Article
Closed access
BLBaoling Lai
Baoling Lai
DYDeliang Yuan
Deliang Yuan
ZXZhiwei Xu
Zhiwei Xu
FZFeilong Zhang
Feilong Zhang
MLMing Li
Ming Li
WGWen-Biao Gan
Wen-Biao Gan

2 September 2024 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
KHKathryn Hockemeyer
Kathryn Hockemeyer
TSTheodore Sakellaropoulos
Theodore Sakellaropoulos
XCXufeng Chen
Xufeng Chen
OIOlha Ivashkiv
Olha Ivashkiv
MSMaria Sirenko
Maria Sirenko
IAIannis Aifantis
Iannis Aifantis

14 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
XCXufeng Chen
Xufeng Chen
JZJingyao Zhao
Jingyao Zhao
CGChan Gu
Chan Gu
YCYu Cui
Yu Cui
YDYuling Dai
Yuling Dai
XLXiaolong Liu
Xiaolong Liu
In response to myeloablative stresses, HSCs are rapidly activated to replenish myeloid progenitors, while maintaining full potential of self-renewal to ensure life-long hematopoiesis. However, the key factors that orchestrate HSC activities during physiological stresses remain largely unknown. Here we report that Med23 controls the myeloid potential of activated HSCs. Ablation of Med23 in hematopoietic system leads to lymphocytopenia. Med23-deficient HSCs undergo myeloid-biased differentiation and lose the self-renewal capacity. Interestingly, Med23-deficient HSCs are much easier to be activated in response to physiological stresses. Mechanistically, Med23 plays essential roles in maintaining stemness genes expression and suppressing myeloid lineage genes expression. Med23 is downregulated in HSCs and Med23 deletion results in better survival under myeloablative stress. Altogether, our findings identify Med23 as a gatekeeper of myeloid potential of HSCs, thus providing unique insights into the relationship among Med23-mediated transcriptional regulations, the myeloid potential of HSCs and HSC activation upon stresses.

1 August 2020
Verified
Conference Paper
Closed access
WLWang Lijia
Wang Lijia
WBWen Binbin
Wen Binbin
CXChen Xufeng
Chen Xufeng
We proposed an adaptive kernel based correlation filter algorithm (AKCF) for object tracking. The algorithm includes two filters: a translation filter and a scale filter. In our method, we classify objects into three categories: fast speed ones, middle speed ones, and low speed ones. To track an object with different speeds, a “padding” value varies accordingly for adjusting the searching area in the translation filter. After detecting an object, the two filters update their parameters for dealing with the appearance variations and scale changes. In the strategy, the response score in the second frame is remembered as a reference, and an updating range is determined. When the current response score is out of the updating range, the filters stop updating to avoid introducing more interference from background. Finally, the proposed method is evaluated on the OTB dataset. Contrary to other state-of-the-art approaches, our method has provided good performance to track an object with different speed and serious scale changes. Additionally, our method is computational efficient.